LanZhou Foci Pharmaceutical Co.,Ltd. (SHE:002644)
8.20
-0.32 (-3.76%)
Aug 21, 2026, 3:04 PM CST
SHE:002644 Revenue
LanZhou Foci Pharmaceutical had revenue of 228.75M CNY in the quarter ending June 30, 2026, with 7.27% growth. This brings the company's revenue in the last twelve months to 926.49M, up 1.73% year-over-year. In the year 2025, LanZhou Foci Pharmaceutical had annual revenue of 915.53M, down -6.60%.
Revenue (ttm)
926.49M
Revenue Growth
+1.73%
P/S Ratio
4.52
Revenue / Employee
695.56K
Employees
1,332
Market Cap
4.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 915.53M | -64.69M | -6.60% |
| Dec 31, 2024 | 980.23M | -182.91M | -15.73% |
| Dec 31, 2023 | 1.16B | 120.75M | 11.58% |
| Jan 1, 2023 | 1.04B | 224.75M | 27.49% |
| Jan 1, 2022 | 817.64M | 149.59M | 22.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 25.24B |
| Jianmin Pharmaceutical Group | 3.35B |
| Jinling Pharmaceutical Company | 3.16B |
| Jinhe Biotechnology CO., LTD. | 2.99B |
| Tibet Weixinkang Medicine | 1.16B |
| Nanjing Hicin Pharmaceutical | 688.74M |
| Zhongzhu Healthcare Holding Co.,Ltd | 544.73M |
| Shanghai Xiao Fang Pharmaceutical | 541.90M |